DOI: http://dx.doi.org/10.18203/2394-6040.ijcmph20184733

Epidemiological, clinical and histopathological features of meningiomas in a tertiary care hospital

Kanwar Sajid Ali, Malik Liaqat Ali Jalal, Sohaib Hassan, Muhammad Kashif

Abstract


Background: Meningiomas are the second most common primary tumors of the central nervous system. These tumors have an inherited tendency to progress and recur. These tumors are more common in females. The aim of this study was to observe the epidemiological, clinical and histopathological features of meningiomas in a tertiary care hospital.

Methods: This observational study was conducted at the Pathology Department of the Postgraduate Medical Institute (PGMI) Lahore, Pakistan, from January 2013 to December 2013. The cases were collected from the Pathology Laboratory of the Lahore General Hospital, Lahore. This study was conducted on 50 cases of histologically diagnosed meningiomas. The sample size was calculated using 15% expected prevalence of meningiomas at 95% confidence interval and 10% level of precision. Data was entered and analyzed using SPSS version 17.

Results: There were 22 (44%) male and 28 (56%) female patients in this study. The mean age of patients was 47.28±14.71 years with the median age 47 years. The minimum and maximum ages were 18 and 75 years and age range was 57 years. Out of 50 cases, fourty two cases were diagnosed as benign meningiomas (WHO Grade-I). Six cases were of atypical meningiomas (WHO grade II). Two cases were diagnosed as anaplastic meningiomas (WHO grade III).

Conclusions: It can be concluded from the findings of present study that meningiomas are more common in females than males with grade I meningiomas outnumber the grade II and grade III meningiomas.


Keywords


Meningiomas, Histological grades, Atypical meningiomas

Full Text:

PDF

References


Nassehi D. Intracranial meningiomas, the VEGF-A pathway, and peritumoral brain oedema. Dan Med J. 2013;60(4):4626.

Frosh PM, Anthony CD, Girolami UD. The central nervous system. In: Kumar V, Abbas AK, Fausto N, Aster JC, eds. Robbins and Cotran Pathological Basis of diseases. 8th Ed. Philadelphia: Elsevier, 2010: 1279-1343.

Jamal S, Mamoon N, Mushtaq S, Luqman M. Pattern of central nervous system (CNS) tumors: a study of 430 cases. Pak J Pathol. 2005;16(4):106-9.

Ahmed Z, Muzaffar S, Kayani N, Pervez S, Husainy AS, Hassan SH. Histological pattern of central nervous system neoplasms. JPMA. 2001;51(4):154–7.

Marosi C, Hassler M, Roessler K, Reni M, Sant M, Mazza E, et al. Meningioma. Crit Rev Oncol Hematol. 2008;67:153–71.

Khalid H, Shibata S, Kishikawa M, Yasunaga A, Iseki M, Hiura T. Immunohistochemical analysis of Progesterone receptor and Ki – 67 labeling index in astrocytic tumors. Cancer. 1997;80(11):2133–40.

Aarhus M, Lund-Johansen M, Knappskog PM. Gene expression profiling of meningiomas: current status after a decade of microarray-based transcriptomic studies. Acta Neurochir. 2011;153(3):447-56.

Ahmed Z, Azad NS, Bhurgari Y, Ahmed R, Kayani N, Pervez S, et al. Significance of Immunohistochemistry in accurate characterization of malignant tumors. J Ayub Med Coll Abbottabad. 2006,18(2):38-43.

Saitoh Y, Oku Y, lzumoto S, Go J. Rapid growth of a meningioma during pregnancy: relationship with estrogen and progesterone receptors-case report. Neurol Med Chir (Tokyo). 1989;29(5):440-3.

Alexiou GA, Markoula S, Gogou P, Kyritsis AP. Genetic and molecular alterations in meningiomas. Clinical Neurol Neurosurge. 2011;113(4):261-7.

Fung KM. Meningiomas Pathology. Medscape reference, 2012.

Wrobel G, Roerig P, Kokocinski F, Neben K, Hahn M, Reifenberger G, et al. Microarray-based gene expression profiling of benign, atypical and anaplatic meningiomas identifies novel genes associated with meningioma progression. Int J Cancer. 2005;114(2):249-56.

Korhonen K, Raitanen J, Isola J, Haapasalo H, Salminen T, Auvinen A. Exogenous sex hormone use and risk of meningioma: a population-based case-control study in Finland. Cancer Causes Control. 2010;21(12):2149-56.

Claus EB, Calvocoressi L, Bondy ML, Wrensch M, Wiemels JL, Schildkraut JM. Exogenous hormone use, reproductive factors, and risk of intracranial meningioma in females. J Neurosurg. 2013;118(3):649-56.

Kubo M, Fukutomi T, Akashi S, Hasegawa T. Association of Breast Cancer with Meningioma: Report of a Case and Review of the Literature. Jpn J Clin Oncol. 2001;31(10):510-3.

Gamble M. The Hematoxylin and Eosin. In; Bancraft JD, Gamble M, eds, 2008. Theory and practice of histological techniques. 6th Ed. New York: Churchill Livingstone; 2008: 121-135.

Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, et al. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol. 2013;15(2):1–56.

Pearson BE, Markert JM, Fisher WS, Guthrie BL, Fiveash JB, Palmer CA, et al. Hitting a moving target: evolution of a treatment paradigm for atypical meningiomas amid changing diagnostic criteria. Neurosurg Focus. 2008;24(5):3.

Claus EB, Bondy ML, Schildkraut JM, Wiemels JL, Wrensch M, Black PM. Epidemiology of intracranial meningioma. Neurosurgery. 2005;57(6):1088–95.

Kaur G, Sayegh ET, Larson A, Bloch O, Madden M, Sun MZ, Barani IJ, James CD, Parsa AT. Adjuvant radiotherapy for atypical and malignant meningiomas: a systematic review. Neuro Oncol. 2014;16(5):628–36.

Thomas Backer-Grondahl, Bjornar H Moen, Sverre H Torp. The histopathological spectrum of human meningiomas. Int J Clin Exp Pathol. 2012;5(3):231-42.

Taghipour M, Rakei SM, Monabati A, Nahavandi-Nejad M. The role of estrogen and progesterone receptors in grading of the malignancy of meningioma. Iranian Red Crescent Med J. 2007;9(1):17-21.

Hilbig A, Maria L, Barbosa-Coutinho. Meningiomas and hormonal receptors- Immunohistochemical study in typical and nontypical tumours. Arq Neuropsiquiatr. 1998;56(2):193-9.

Telugu RB, Chowhan AK, Rukmangadha N, Patnayak R. Histopathological and immunohistochemical evaluation of meningiomas with Reference to Proliferative Markers p53 and Ki-67. J Clin Diagnos Res. 2016;10(1):15-9.

Norden AD, Drappatz J, Wen PY. Targeted drug therapy for meningiomas. Neurosurg Focus 2007;23(4):12.

Fewings PE, Battersby RDE, Timperley WR. Long-term follow up of progesterone receptor status in benign meningioma: a prognostic indicator of recurrence? J Neurosurg. 2000;92:401-5.

Hsu DW, Efird JT, Hedley-Whyte ET. Progesterone and estrogen receptors in meningiomas: prognostic considerations. J Neurosurge. 1997;86(1):113-20.

Metellus P, Nanni I, Dussert C, Trinkhaus M, Fuentes S, Chinot O, et al. Prognostic implications of biologic markers in intracranial meningiomas: 120 Cases. Neurochirurgie. 2008;54(6):750-6.

Omulecka A, Papierz W, Nawrocka-Kunecka A, Lewy-Trenda I. Immuno-histochemical expression of progesterone and estrogen receptors in meningiomas. Folia Neuropathol. 2006;44(2):111-5.